A152T‐variant human tau (hTau‐A152T) increases risk for tauopathies, including Alzheimer's disease. Comparing mice with regulatable expression of hTau‐A152T or wild‐type hTau (hTau‐WT), we find age‐dependent neuronal loss, cognitive impairments, and spontaneous nonconvulsive epileptiform activity primarily in hTau‐A152T mice. However, overexpression of either hTau species enhances neuronal responses to electrical stimulation of synaptic inputs and to an epileptogenic chemical. hTau‐A152T mice have higher hTau protein/mRNA ratios in brain, suggesting that A152T increases production or decreases clearance of hTau protein. Despite their functional abnormalities, aging hTau‐A152T mice show no evidence for accumulation of insoluble tau aggregates, suggesting that their dysfunctions are caused by soluble tau. In human amyloid precursor protein (hAPP) transgenic mice, co‐expression of hTau‐A152T enhances risk of early death and epileptic activity, suggesting copathogenic interactions between hTau‐A152T and amyloid‐β peptides or other hAPP metabolites. Thus, the A152T substitution may augment risk for neurodegenerative diseases by increasing hTau protein levels, promoting network hyperexcitability, and synergizing with the adverse effects of other pathogenic factors.
See also: JM Decker et al
A mouse model of A152T‐variant human tau suggests that the mutation augments the risk for neurodegenerative diseases by increasing neuronal levels of soluble hTau, promoting network hyperexcitability, and synergizing with adverse effects of other pathogenic factors.
Cortical and hippocampal hTau protein/mRNA ratios are higher and hTau fragment levels lower in hTau‐A152T than hTau‐WT mice.
hTau‐A152T mice show age‐dependent neuronal loss, astrocytosis, nonconvulsive epileptiform activity and cognitive impairments, but no accumulation of insoluble, fibrillar tau.
In human amyloid precursor protein (hAPP) transgenic mice, co‐expression of hTau‐A152T worsens premature mortality and epileptic activity, suggesting co‐pathogenic interactions between hTau‐A152T and amyloid‐β peptides or other hAPP metabolites.
- Received September 23, 2015.
- Revision received December 1, 2015.
- Accepted January 13, 2016.
- © 2016 The Authors